Abstract:Targeting the menin-MLL protein–protein interaction is being pursued as a new therapeutic strategy for the treatment of acute leukemia carrying MLL-rearrangements (MLLr leukemia). Herein, we report M-1121, a covalent and orally active inhibitor of the menin-MLL interaction capable of achieving complete and persistent tumor regression. M-1121 establishes covalent interactions with Cysteine 329 located in the MLL binding pocket of menin and potently inhibits growth of acute leukemia cell lines carrying MLL translocations with no activity in cell lines with wild-type MLL. Consistent with the mechanism of action, M-1121 drives dose-dependent down-regulation of HOXA9 and MEIS1 gene expression in the MLL-rearranged MV4;11 leukemia cell line. M-1121 is orally bioavailable and shows potent antitumor activity in vivo with tumor regressions observed at tolerated doses in the MV4;11 subcutaneous and disseminated models of MLL-rearranged leukemia. Together, our findings support development of an orally active covalent menin inhibitor as a new therapy for MLLr leukemia.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00789?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00789</a>.Crystallography data collection and refinement statistics. In vivo pharmacokinetics and efficacy data of compounds 10, 17, 24 (M-1121) in mice. Purity and spectral data of M-1121. Method for computational modeling for compounds 24 and 25 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00789/suppl_file/jm1c00789_si_001.pdf">PDF</a>)A molecular string file for all the final target compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00789/suppl_file/jm1c00789_si_002.csv">CSV</a>)Modeled structures of compounds 24 and 25 in complex with the menin protein (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00789/suppl_file/jm1c00789_si_003.pdb">PBD</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00789/suppl_file/jm1c00789_si_004.pdb">PBD</a>)This article has not yet been cited by other publications.

Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (wdr5)–mixed Lineage Leukemia (MLL) Protein–Protein Interaction

Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction.

High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction.

High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.

Discovery of DDO-2213 As a Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia

Structure-Based Design and Synthesis of Small Molecular Inhibitors Disturbing the Interaction of Mll1-Wdr5

Computational Studies of Novel Aniline Pyrimidine WDR5-MLL1 Inhibitors: QSAR, Molecular Docking, and Molecular Dynamics Simulation

Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.

Structure-Based Design of High-Affinity Macrocyclic Peptidomimetics to Block the Menin-Mixed Lineage Leukemia 1 (mll1) Protein-Protein Interaction

Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with <i>in vivo</i> antitumor activity

Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models

Targeting MLL1 H3K4 Methyltransferase Activity in Mixed-Lineage Leukemia.

Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions Between DOT1L and MLL-AF9/MLL-ENL.

Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth

Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression

Identification of 5-Thiocyanatothiazol-2-amines Disrupting WDR5-MYC Protein-Protein Interactions.

Research Progress on Small Molecule Inhibitors of MLL1-WDR5 Interaction

Discovery of M-808 As a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong in Vivo Antitumor Activity.

Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia in Vivo.

Pharmacological targeting of the Wdr5-MLL interaction in C/EBP[alpha] N-terminal leukemia

Screening and Optimization of Phage Display Cyclic Peptides Against the WDR5 WBM Site